{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:29:38Z","timestamp":1776486578798,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001736","name":"German-Israeli Foundation for Scientific Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1053\/j.jvca.2022.07.022","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T02:06:12Z","timestamp":1658455572000},"page":"4496-4500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin II - A Brief Review and Role in Severe SARS-COV-2 Sepsis"],"prefix":"10.1053","volume":"36","author":[{"given":"Gianmarco A.","family":"Car\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Alborino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Zarbock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8594-5980","authenticated-orcid":false,"given":"Giovanni","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2022.07.022_bib0001","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2022.07.022_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-018-0297-9","article-title":"FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock","volume":"19","author":"Senatore","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2022.07.022_bib0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2022.07.022_bib0004","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1053\/j.jvca.2022.07.022_bib0005","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor\u2013dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2022.07.022_bib0006","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2022.07.022_bib0007","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","article-title":"Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II","volume":"20","author":"Hunyady","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1053\/j.jvca.2022.07.022_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1213\/ANE.0000000000005953","article-title":"The association between angiotensin II and renin kinetics in patients after cardiac surgery","volume":"134","author":"Meersch","year":"2022","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2022.07.022_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: New roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1053\/j.jvca.2022.07.022_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0025-7125(16)30093-1","article-title":"The endocrine response to critical illness","volume":"79","author":"Rolih","year":"1995","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.jvca.2022.07.022_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-015-0802-3","article-title":"Angiotensin II in septic shock","volume":"19","author":"Corr\u00eaa","year":"2015","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0012","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1053\/j.jvca.2022.07.022_bib0013","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3390\/cells10071767","article-title":"Renin-angiotensin-aldosterone system and immunomodulation: A state-of-the-art review","volume":"10","author":"Laghlam","year":"2021","journal-title":"Cells"},{"key":"10.1053\/j.jvca.2022.07.022_bib0014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1994.1013","article-title":"Assay of pulmonary microvascular endothelial angiotensin-converting enzyme in vivo: Comparison of three probes","volume":"124","author":"Orfanos","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1053\/j.jvca.2022.07.022_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13054-019-2420-y","article-title":"Broad spectrum vasopressors: A new approach to the initial management of septic shock?","volume":"23","author":"Chawla","year":"2019","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0016","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13613-019-0536-5","article-title":"Sensitivity to angiotensin II dose in patients with vasodilatory shock: A prespecified analysis of the ATHOS-3 trial","volume":"9","author":"Ham","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0018","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II","volume":"46","author":"Tumlin","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2022.07.022_bib0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13054-020-02928-0","article-title":"Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series","volume":"24","author":"Zangrillo","year":"2020","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0020","first-page":"215","article-title":"Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients","volume":"23","author":"Zangrillo","year":"2021","journal-title":"Crit Care Resusc"},{"key":"10.1053\/j.jvca.2022.07.022_bib0021","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/jmv.27592","article-title":"Angiotensin II infusion in COVID-19: An international, multicenter, registry-based study","volume":"94","author":"Serpa Neto","year":"2022","journal-title":"J Med Virol"},{"key":"10.1053\/j.jvca.2022.07.022_bib0022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13054-020-02862-1","article-title":"COVID-19 and the RAAS-a potential role for angiotensin II?","volume":"24","author":"Busse","year":"2020","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0023","first-page":"388","article-title":"Feasibility and safety of angiotensin II administration in general ward patients during COVID-19 pandemic: A case series","volume":"22","author":"Morselli","year":"2020","journal-title":"Crit Care Resusc"},{"key":"10.1053\/j.jvca.2022.07.022_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s13054-020-03143-7","article-title":"Angiotensin II treatment in COVID-19 patients: More risk than benefit? A single-center experience","volume":"24","author":"Heinicke","year":"2020","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2022.07.022_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1152\/physiolgenomics.00057.2004","article-title":"Cardiac transcriptional response to acute and chronic angiotensin II treatments","volume":"18","author":"Larkin","year":"2004","journal-title":"Physiol Genomics"},{"key":"10.1053\/j.jvca.2022.07.022_bib0026","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2022.07.022_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/14728220903460332","article-title":"Modulation of the renin-angiotensin-aldosterone system in sepsis: A new therapeutic approach?","volume":"14","author":"Salgado","year":"2010","journal-title":"Expert Opin Ther Targets"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077022005390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077022005390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:11:06Z","timestamp":1762355466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077022005390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1053077022005390"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2022.07.022","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin II - A Brief Review and Role in Severe SARS-COV-2 Sepsis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2022.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}